Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

May

Today In Oncology

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Amit Sanyal, MD: A Clinician’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer

ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial

Behind the Scenes of the 2026 ASCO Annual Meeting

First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations